Cardio-facio-cutaneous (CFC) syndrome, a genetic disorder caused by germline mutations in BRAF, KRAS, MAP2K1 and MAP2K2, is characterized by growth retardation, heart defects, dysmorphic facial appearance and dermatologic abnormalities. We have previously reported that knock-in mice expressing the CFC syndrome-associated mutation, Braf Q241R, showed growth retardation because of gastrointestinal dysfunction. However, other factors associated with growth retardation, including chondrogenesis and endocrinological profile, have not been examined. Here, we show that 3-and 4-week-old Braf Q241R/+ mice have decreased body weight and length, as well as reduced growth plate width in the proximal tibiae. Furthermore, proliferative and hypertrophic chondrocyte zones of the growth plate were reduced in Braf Q241R/+ mice compared with Braf +/+ mice. Immunohistological analysis revealed that extracellular signal-regulated kinase (ERK) activation was enhanced in hypertrophic chondrocytes in Braf Q241R/+ mice. In accordance with growth retardation and reduced growth plate width, decreased serum levels of insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3) were observed in Braf Q241R/+ mice at 3 and 4 weeks of age. Treatment with C-type natriuretic peptide (CNP), a stimulator of endochondral bone growth and a potent inhibitor of the FGFR3-RAF1-MEK/ERK signaling, increased body and tail lengths in Braf +/+ and Braf Q241R/+ mice. In conclusion, ERK activation in chondrocytes and low serum IGF-1/IGFBP-3 levels could be associated with the growth retardation observed in Braf Q241R/+ mice. Our data also suggest that CNP is a potential therapeutic target in CFC syndrome.
Introduction
Longitudinal bone growth occurs by endochondral ossification, in which mesenchymal progenitor cells condense, proliferate and differentiate into growth plate chondrocytes, which are subsequently progressively replaced by bone (1) . During this process, chondrocytes give rise to resting chondrocytes, columns of proliferating chondrocytes and hypertrophic chondrocytes. The zones of proliferating and hypertrophic chondrocytes express type II collagen and type X collagen, respectively. Hypertrophic chondrocytes proceed to the formation of mineralized matrix and apoptosis, which lead to replacement by bone (1) .
The RAS/mitogen-activated protein kinase (MAPK) signaling pathway has been shown to play a crucial role in endochondral ossification. A mouse model of achondroplasia (dwarfism) with an activated FGFR3 mutation has been shown to have achondroplasia-associated phenotypes, short stature, skeletal abnormalities and a narrower hypertrophic zone in the growth plate because of MEK/extracellular signal-regulated kinase (ERK) activation (2) . Cartilage-specific (Col2a1-Cre) mice expressing a constitutively active MEK1 mutation exhibit short stature and shorter zones of hypertrophic chondrocytes in the growth plate (3) . These observations suggest that MEK/ERK activation in chondrocytes leads to impaired endochondral ossification, resulting in short stature.
Short stature and growth retardation are common clinical features observed in patients with RASopathies, a group of genetic syndromes with dysregulation of the RAS/MAPK signaling pathway (4) (5) (6) (7) . RASopathies include Noonan syndrome, Noonan syndrome with multiple lentigines, cardio-facio-cutaneous (CFC) syndrome, Costello syndrome, neurofibromatosis type 1 (NF1) and Legius syndrome (4) (5) (6) (7) (8) . Among the RASopathies, CFC syndrome typically presents as short stature, severe growth retardation, congenital heart defects, distinctive facial features and ectodermal abnormalities (9, 10) . Germline activating mutations in BRAF, KRAS, MAP2K1 and MAP2K2 have been identified in CFC syndrome (11, 12) . Approximately 70% of patients with CFC syndrome have BRAF mutations (13, 14) . We have previously demonstrated that knock-in mice expressing the CFC syndromeassociated Braf Q241R mutation (Braf Q241R/+ ) exhibit the characteristic phenotypes of CFC syndrome, including growth retardation, heart defects (cardiomegaly, pulmonary valve stenosis and atrial septal defects), craniofacial dysmorphism, learning deficits, sparse and ruffled fur and a hunched appearance (15) . Furthermore, Braf Q241R/+ mice developed growth retardation because of feeding problems and gastrointestinal abnormalities, including esophageal dilation and gastric epithelial hyperplasia (16) . Noonan syndrome patients with PTPN11 mutations respond less efficiently to growth hormone (GH), than PTPN11 mutationnegative patients, although GH secretion status in Noonan syndrome is commonly normal (17) . Furthermore, most Noonan syndrome patients with PTPN11 mutations show low insulinlike growth factor 1 (IGF-1) levels (17) . Indeed, it has been reported that Ptpn11 D61G/+ mice, a mouse model of Noonan syndrome, show growth retardation, decreased IGF-1 levels and impaired chondrocyte differentiation during endochondral bone growth (18, 19 The GH/IGF-1 axis is associated with the primarily regulation of postnatal growth because of chondrogenesis in the growth plate (27) . Patients and mice with Noonan syndromeassociated PTPN11 mutations have been reported to have short stature and reduced IGF-1 levels (19, 28 were no differences in the levels of IGF-1 and IGFBP-3 at 6 and 12 weeks of age. Indeed, a difference in growth velocity between Braf +/+ and Braf Q241R/+ mice is observed with a peak at 3 or 4 weeks of age (15) . Notably, serum IGF-1 and IGFBP-3 levels were positively correlated with body weight in Braf Q241R/+ mice at 
CNP treatment leads to increased body length and tail length in Braf Q241R/+ mice
Our previous studies have indicated that treatment with MEK inhibitors ameliorates growth retardation, bone abnormalities and gastrointestinal abnormalities in Braf Q241R/+ mice (15, 30) ; that is, the inhibition of MEK/ERK activation may also improve impaired endochondral bone growth. CNP, a member of the Braf +/+ (males n = 4, females n = 2) and Braf Q241R/+ (males n = 4, females n = 2) mice at 3 weeks of age. * P < 0.05; * * * P < 0.001 versus Braf +/+ . natriuretic peptide family, is known to have the ability to stimulate endochondral bone growth and long bone growth (31) . CNP has also been reported to inhibit FGF signaling through inhibition of ERK activation at the level of RAF1 (32, 33 Fig. 3B and C) .
The growth velocities in Braf +/+ /CNP (1.0) and Braf Q241R/+ /CNP (1.0) mice were comparable during the 4-week treatment period ( Fig. 3B and C) . CNP treatment had no effects on body weight in Braf +/+ and Braf Q241R/+ mice (Fig. 3D) . (Fig. 3E) . We next examined the histology of the epiphyseal growth plate of the proximal tibiae in Braf +/+ /CNP (1.0) and Braf Q241R/+ / CNP (1.0) mice. Unlike the postnatal period (at 3-4 weeks of age), no significant differences in the width of the growth plate, proliferative zone and hypertrophic zone were observed between Braf +/+ /vehicle and Braf Q241R/+ /vehicle mice at 9 weeks of age ( Fig. 4A-C) . The growth plate and proliferative zone, but not the hypertrophic zone, in Braf +/+ /CNP (1.0) mice were significantly thicker than those in Braf +/+ /vehicle mice ( Fig. 4A-C showed sustained ERK phosphorylation in hypertrophic zones (Fig. 5A) . Furthermore, Ki67-positive cells in the proliferative and hypertrophic zones were not observed in all groups (Fig. 5B) .
Discussion
In Mice deficient in chondrocyte-specific ERK1/2 have been reported to develop kyphosis, deformed rib cages and expansion of the hypertrophic zone in the growth plate (23), whereas chondrocyte-specific activation of MEK1 in mice has been shown to cause growth retardation and a reduced hypertrophic zone without affecting chondrocyte proliferation (3). The importance of the regulation of the RAS/MAPK signaling pathway in endochondral ossification has also been reported in mouse models of RASopathies. Mice lacking NF1 in chondrocytes (NF1 model) display dwarfism, decreased chondrocyte proliferation and maturation, and activation of phosphorylated ERK1/2 in the growth plate (22 MEK/ERK signaling pathway through BRAF could be essential for normal endochondral ossification (chondrocyte differentiation), but not chondrocyte proliferation, in growth plate cartilage. The GH/IGF-1 signaling system plays an important role in postnatal bone growth (27) . Knockout mice of the IGF-1 or GH receptor and double knockout mice have been found to exhibit decreased body weight and length, as well as decreased growth plate width with narrower zones of proliferative and hypertrophic chondrocytes (34) . Patients with CFC syndrome only rarely have GH deficiency (20, 21 low IGF-1 and IGFBP-3 serum levels at 3-4 weeks of age, although GH levels were comparable in Braf +/+ and Braf Q241R/+ mice. Furthermore, there was a positive correlation between body weight and serum IGF-1/IGFBP-3 levels in Braf Q241R/+ mice at 3-4 weeks of age. Indeed, consistent with the normal IGF-1 and IGFBP-3 levels in Braf Q241R/+ mice at 6 and 12 weeks of age, we did not observe a difference in growth velocity and growth plate width between Braf +/+ and Braf Q241R/+ mice at 9 weeks of age. Decreased IGF-1 levels and normal or elevated GH levels have been found in states of undernutrition, including starvation, protein deficiency, vitamin deficiency and anorexia nervosa, suggesting a positive association between energy intake and IGF-1 levels, but not GH levels (35) . Recently, it has been reported that Ptpn11 D61G/+ mice at postnatal stages display short stature, decreased growth plate width and low IGF-1 and IGFBP-3 serum levels, which are similar findings to those of our studies (18, 19) . Furthermore, IGF-1 treatment rescued the reduced body length and decreased growth plate width in Ptpn11 D61G/+ mice (18) . Collectively, low IGF-1 and IGFBP-3 levels because of poor nutrition could be responsible for growth retardation and decreased growth plate width in Braf Q241R/+ mice at postnatal stages.
CNP is considered as a therapeutic target for achondroplasia (33) . CNP treatment has been found to improve the growth failure and short stature in achondroplasia (Fgfr3 Y367C/+ ) and NF1 model mice (2). BMN111, a CNP analog, recovered the phenotypes of reduced body length and bone growth in Fgfr3 Y367C/+ mice. Furthermore, BMN111 inhibited FGF2-mediated ERK1/2 activation in primary growth plate chondrocytes isolated from achondroplasia patients (2). NC-2, a CNP recombinant, rescued growth retardation in chondrocyte-specific NF1-deficient mice because of reduced phosphorylated ERK in the growth plate (22) . These data suggest that CNP enhances endochondral bone growth because of ERK inhibition. Our results suggest that CNP treatment in Braf Q241R/+ mice leads to increase in body and tail lengths. However, we did not detect significant increases in growth plate width and decreases in phosphorylated ERK1/2 in the hypertrophic chondrocytes of Braf Q241R/+ mice. It is possible that ERK1/2 inhibition and expansion of the growth plate width could occur in the early stages of CNP treatment.
CNP, a potent stimulator of endochondral ossification, is expressed in the growth plate of long bones and a variety of tissues, including brain and female reproductive tissues (31, 36) . The CNP/natriuretic peptide receptor 2 (NPR2; CNP receptor)-mediated intracellular cGMP pathway has been shown to regulate endochondral bone formation (37) Fig. S3B ). Chondrocyte-specific activation of CNP in mice (Col2a1-CNP Tg) showed overgrowth of long bones and the vertebrae because of increased width in growth plates. Igf1 mRNA levels from primary chondrocytes were comparable in control and Col2a1-CNP Tg mice (38) . Furthermore, patients with a NPR2 V883M mutation, a gain-of-function mutation, have been reported to have tall stature, scoliosis and normal IGF-l levels (39) . Taken together, these studies suggest that CNP treatment or overexpression of CNP and NPR2 may lead to bone growth through IGF-1-independent mechanisms. In addition to the effects of bone growth, CNP has been reported to have an important role in cardiac disease and gastrointestinal function (40, 41 
Materials and Methods

Animals
Braf Q241R/+ mice on an ICR background expressing the most common BRAF Q257R (Q241R in mice) mutation observed in patients with CFC syndrome were described previously (15, 30) . ICR mice were purchased from Charles River Laboratories Japan (Yokohama, Japan). All mice were maintained under a 12 h light/12 h dark cycle, specific pathogen-free conditions and fed a Labo MR Stock (Nihon Nosan Kogyo, Yokohama, Japan). Unless otherwise noted, male mice were used. All animal experiments were approved by the Animal Care and Use Committee of Tohoku University.
CNP
Human CNP consisting of 53 amino acids was produced at the C-terminus of the partner peptides involving amino acids 1 to 118 of a modified Escherichia coli β-galactosidase by linker peptides GKSKHKR. The fusion proteins in the inclusion bodies were rendered soluble with lauroyl sarcosine and subjected to site-specific cleavage with the secretory type yeast Kex2 protease. The cleaved peptide was harvested by adding urea and β-cyclodextrin. After 0.45 μm filtration, the CNP-53 was roughly purified by strong cation-exchange chromatography and oxidized by stirring at pH9.0 for overnight. The cyclic CNP-53 was purified by reversed-phase column. Its purity analyzed by highperformance liquid chromatography was 96.1%, and its amino acid composition was verified by electrospray ionization mass spectrometry.
CNP treatment
All mice were housed single per cage after weaning (4-week-old). CNP (0.33 or 1.0 mg/kg/day) or ultra-pure water was administered subcutaneously for 28 days using mini-osmotic pumps (Model 1004, ALZET tech, Cupertino, CA, USA) in 5-week-old mice. Body weight, body length (nasal-anal distance) and tail length were measured under isoflurane anesthesia.
Measurement of plasma CNP
Blood samples were collected in Capiject tubes (CJ-NA; Terumo, Tokyo, Japan) and centrifuged at 1200 × g for 30 min at 4
• C.
The supernatant (plasma) was stored at −80 • C until use. The plasma concentration of CNP was quantified by radioimmunoassay (RIA). The CNP RIA was conducted using antiserum that recognized the 17-member, internal disulfide ring of CNP, with 
Histology
Dissected bones were fixed in 10% neutral buffered formalin, decalcified in EDTA and embedded in paraffin. Bone sections (3-4 μm) of the tibial growth plate were stained with Alcian blue 8GS or hematoxylin and eosin.
Immunohistochemistry
For antigen retrieval, dewaxed sections were treated with bovine testicular hyaluronidase (Sigma) or Histofine antigen retrieval solution (Nichirei Bio Sciences). Anti-phospho-ERK (catalog number (cat) #4376), Ki67 (cat #418071) and type X collagen (cat #14-9771-80) antibodies were obtained from Cell Signaling (Danvers, MA, USA), Nichirei Bio Sciences and eBioscience (San Diego, CA, USA), respectively. The Histofine simple stain kit (Nichirei Bio Sciences) was used for detection, and the signals were visualized by using a DAB substrate kit (Nichirei Bio Sciences). Type II collagen assays were performed using a collagen staining kit (cat #9001; Chondrex Inc., Redmond, WA, USA) according to the manufacturer's protocol.
Enzyme-linked immunosorbent assay (ELISA)
Blood samples were collected in Capiject tubes (CJ-AS; Terumo, Tokyo, Japan) and centrifuged at 1200 × g for 15 min at 15
• C. The supernatant (serum) was stored at −80 • C until use. Serum levels of IGF-1 (R&D systems, Minneapolis, MN, USA), IGFBP-3 (R&D systems) and GH (Millipore, St Louis, MO, USA) were measured using ELISA kits according to the manufacturer's instructions.
Statistical analysis
Statistical analyses of the data were conducted using Prism software (ver. 6.01; GraphPad Software, Inc., San Diego, CA).
Comparison of data was performed with Student's t-test, Welch's t-test or the Mann-Whitney U-test between two groups or a oneway analysis of variance followed by the Tukey-Kramer test for comparisons between multiple experimental groups. All data are shown as the mean ± standard deviation (SD). P-values < 0.05 were considered statistically significant differences.
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